求翻译：另外，德国勃林格殷格翰药业有限公司有2项直接相关专利尚未进入任何国家（PCT均曾指向中国，但目前欧洲专利局网站显示没有进入中国、已过优先权日），相关专利的权利要求保护了沙丁胺醇和异丙托溴铵的无推进剂的溶液型制剂，溶剂选自水、乙醇、水-乙醇混合物，沙丁和异溴比例范围是2:1-3:1和5：1-5.5：1，如处方溶剂与此不同（或者主药的处方比例在其权利要求之外）就可以避开此专利。是什么意思？

In addition, Boehringer Ingelheim Pharmaceutical Co., Ltd. has two directly related to the patent has not yet entered any country (PCT have all been directed at China, but did not enter the European Patent Office site shows in China, the priority date has passed), the relevant patent rights for the

正在翻译，请等待...

正在翻译，请等待...

Also, Germany bolinge Yin Gehan drug industry limited has 2 item directly related patent has not been entered any national (PCT are had links to China, but currently European Patent Office website display no entered China, and has had priority day), related patent of right requirements protection ha

正在翻译，请等待...